The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis

Eric A F Simões

DOI: https://doi.org/10.1093/infdis/jiac211

2022-08-16

Abstract:Although pediatricians have long recognized that respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children, the most important cause of acute illness visits to their clinics, and the most important cause of hospitalizations during the respiratory season, we have been resigned for the last 4 decades to patiently waiting while other viral and bacterial diseases have been conquered by successful vaccines [1]. The seminal discovery of the stabilized prefusion form of the RSV F protein [2] occurring simultaneously with advances in immunology and structural biology have very quickly led to the development of long-acting monoclonal antibodies for infants [3–5] and vaccines for immunizing pregnant mothers [6, 7], both of which strategies target the prevention of RSV LRTI in infants. Palivizumab, a monoclonal antibody to be administered once a month [8, 9], although available since 1998, has only been used for prevention in select groups of high-risk infants and young children [10]. However, the vast majority of the burden of disease occurs in healthy full-term infants hitherto not eligible for this efficacious modality. Recent successful phase II and III studies of a long-acting monoclonal antibody (nirsevimab) [11–13] and phase II and III studies of maternal immunization [14, 15] provide imminent hope that we will at last be able to prevent severe disease caused by RSV in all infants. This paradigm shift necessitates a thorough review of the literature pertaining to the burden of disease, the cost to the healthcare system and to families, and the morbidity and mortality caused by RSV in all infants, as presented in this supplement.

immunology,infectious diseases,microbiology